U.K. cancer-drug fund widely underused; Patients join fight against MA coupon ban;

@FiercePharma: Are drugmakers suffering from complexity? Item | Follow @FiercePharma

> The U.K.'s million pound fund set up to increase uptake of new cancer drugs was widely underused, with just over half of the allocated money spent. News

> Patient groups are joining the pharmaceutical industry in an effort to overturn another Massachusetts ban: A bar against drug coupons. Story

> Watson Pharmaceuticals said a federal court denied Teva Pharmaceutical's request for an injunction against Watson's launch of a generic version of the contraceptive Seasonique. Watson release

> Celgene said it received FDA approval to expand the use of its Istodax drug in the treatment of blood cancers. Item

> Pozen said Indian drugmaker Lupin has filed with U.S. health regulators for a copycat version of its pain drug Vimovo, in the second generic threat to the drug. Article

> For 100 years, Johnson & Johnson has grown at an average rate of 10 to 11 percent. But that growth rate may be a thing of the past. News

> Pharma retailer Celesio saw its shares plummet nearly 13 percent after it issued a profit warning and said it had underestimated competition in Germany's pharmaceuticals wholesale business due to healthcare reforms there. Report

Biotech News

@FierceBiotech: Type I diabetes nasal vaccine on the horizon. Article | Follow @FierceBiotech

@JohnCFierce: I hate to see "miracle treatment" in a headline about a scientific breakthrough. Ain't no such thing. Follow @JohnCFierce

> Pfizer, BMS forthcoming data on apixaban has analysts on alert. Report

> Analyst bets on approval of Pfizer's lung cancer drug. News

> NC, Indy officials pitch plans to aid life sciences. Article

And Finally... While people in Japan, Canada, and other nations are enjoying significant gains in life expectancy every year, most counties within the U.S. are falling behind. Report

Suggested Articles

BMS’s Opdivo has plenty of competition in its current bladder cancer indication—so it’s hoping to strike out on its own in a new area of the disease.

The Japanese approval, under the brand name Jyseleca, came a month after an FDA complete response letter that asked Gilead for more data.

The Trump Administration has opened the doors for Florida and other states to import prescription drugs from Canada—despite industry objections.